28332137|t|Correction of dilutional anemia induces renal dysfunction in diabetic patients undergoing coronary artery bypass grafting: a consequence of microcirculatory alterations?
28332137|a|In this study we aimed to evaluate the effects of dilutional anemia resulting from cardiopulmonary bypass (CPB) and its correction with red blood cell (RBC) transfusion on tissue oxygenation and renal function in diabetic patients undergoing coronary artery bypass grafting (CABG). 70 diabetic patients who underwent elective CABG and whose hematocrit values had been between 24-28% at any time during CBP were prospectively randomized and equally allocated to two groups: patients who received RBC during CPB (group I, n = 35) vs. did not receive RBC during CPB (group II, n = 35). Besides routine hemodynamic and biochemical parameters, biomarkers of ischemia and renal injury such as ischemia modified albumin (IMA), protein oxidation parameters [advanced oxidative protein products (AOPP), total thiol (T-SH)], neutrophil gelatinase-associated lipocalin (NGAL) and estimated glomerular filtration rate (eGFR) were measured in both groups. In group I, T-SH, NGAL and urea levels were found to be significantly increased postoperatively compared to preoperative measurements (p < 0.05). Also, postoperatively, NGAL, creatinine, aspartate aminotransferase and AOPP levels were higher in group I than group II (p < 0.05). The correction of anemia with RBC transfusion in diabetic patients undergoing CABG could increase the risk of renal injury. Further studies verifying the effects of blood transfusions at the microcirculatory level are needed to optimize the efficacy of transfusions.
28332137	14	31	dilutional anemia	T047	C0472711
28332137	40	57	renal dysfunction	T033	C3279454
28332137	61	69	diabetic	T047	C0011847
28332137	70	78	patients	T101	C0030705
28332137	90	121	coronary artery bypass grafting	T061	C0010055
28332137	140	156	microcirculatory	T042	C0025962
28332137	178	183	study	T062	C2603343
28332137	209	219	effects of	T080	C1704420
28332137	220	237	dilutional anemia	T047	C0472711
28332137	253	275	cardiopulmonary bypass	T061	C0007202
28332137	277	280	CPB	T061	C0007202
28332137	306	338	red blood cell (RBC) transfusion	T061	C0086252
28332137	342	360	tissue oxygenation	T042	C0872293
28332137	365	379	renal function	T042	C0232804
28332137	383	391	diabetic	T047	C0011847
28332137	392	400	patients	T101	C0030705
28332137	412	443	coronary artery bypass grafting	T061	C0010055
28332137	445	449	CABG	T061	C0010055
28332137	455	463	diabetic	T047	C0011847
28332137	464	472	patients	T101	C0030705
28332137	496	500	CABG	T061	C0010055
28332137	511	528	hematocrit values	T033	C0518014
28332137	572	575	CBP	T061	C0007202
28332137	635	641	groups	T078	C0441833
28332137	643	651	patients	T101	C0030705
28332137	665	668	RBC	T025	C0014792
28332137	676	679	CPB	T061	C0007202
28332137	681	688	group I	T078	C0441833
28332137	718	721	RBC	T025	C0014792
28332137	729	732	CPB	T061	C0007202
28332137	734	742	group II	T078	C0441833
28332137	769	780	hemodynamic	T042	C0019010
28332137	797	807	parameters	T077	C0549193
28332137	823	831	ischemia	T046	C0022116
28332137	836	848	renal injury	T037	C0160420
28332137	857	882	ischemia modified albumin	T116	C3266190
28332137	884	887	IMA	T116	C3266190
28332137	890	907	protein oxidation	T044	C1159301
28332137	908	918	parameters	T077	C0549193
28332137	920	955	advanced oxidative protein products	T109	C1976991
28332137	957	961	AOPP	T109	C1976991
28332137	964	975	total thiol	T123	C0574031
28332137	977	981	T-SH	T123	C0574031
28332137	985	1027	neutrophil gelatinase-associated lipocalin	T116,T123	C0215955
28332137	1029	1033	NGAL	T116,T123	C0215955
28332137	1039	1075	estimated glomerular filtration rate	T059	C3811844
28332137	1077	1081	eGFR	T059	C3811844
28332137	1088	1096	measured	T080	C0444706
28332137	1105	1111	groups	T078	C0441833
28332137	1116	1123	group I	T078	C0441833
28332137	1125	1129	T-SH	T123	C0574031
28332137	1131	1135	NGAL	T116,T123	C0215955
28332137	1140	1151	urea levels	T034	C0428275
28332137	1183	1192	increased	T081	C0205217
28332137	1193	1208	postoperatively	T079	C0032790
28332137	1221	1233	preoperative	T079	C0445204
28332137	1234	1246	measurements	T169	C0242485
28332137	1265	1280	postoperatively	T079	C0032790
28332137	1282	1286	NGAL	T116,T123	C0215955
28332137	1288	1298	creatinine	T109,T123	C0010294
28332137	1300	1326	aspartate aminotransferase	T116,T126	C0004002
28332137	1331	1335	AOPP	T109	C1976991
28332137	1348	1354	higher	T080	C0205250
28332137	1358	1365	group I	T078	C0441833
28332137	1371	1379	group II	T078	C0441833
28332137	1410	1416	anemia	T047	C0002871
28332137	1422	1437	RBC transfusion	T061	C0086252
28332137	1441	1449	diabetic	T047	C0011847
28332137	1450	1458	patients	T101	C0030705
28332137	1470	1474	CABG	T061	C0010055
28332137	1494	1498	risk	T078	C0035647
28332137	1502	1514	renal injury	T037	C0160420
28332137	1546	1556	effects of	T080	C1704420
28332137	1557	1575	blood transfusions	T061	C0005841
28332137	1583	1599	microcirculatory	T042	C0025962
28332137	1633	1641	efficacy	T080	C1280519
28332137	1645	1657	transfusions	T061	C1879316